1. A liquid crystal display device comprising:
a first substrate comprising:
a plurality of data electrodes;
a plurality of gate electrodes arranged to intersect the data electrodes; and
a plurality of pixels, each of the pixels including a thin film transistor and a pixel electrode, each of the pixels coupled to one of the data lines and one of the gate lines;
a second substrate facing the first substrate, the second substrate comprising:
a plurality of color filters, each of the color filters facing one of the pixel electrodes; and
a black matrix formed on a region in which the color filters are not formed, the black matrix having openings that expose the gate electrodes; and
a liquid crystal layer disposed between the first substrate and the second substrate,
wherein the openings alternate on opposite sides of the color filters with no openings adjacent to each other.
2. The liquid crystal display device as claimed in claim 1, wherein one of the pixels disposed by one side of a first one of the data electrodes is coupled to a first one of the gate electrodes, and another of the pixels disposed by an opposite side of the first one of the data electrodes is coupled to a second one of the gate electrodes.
3. The liquid crystal display device as claimed in claim 2, wherein both of the one of the pixels and the another of the pixels are coupled to the first one of the data electrodes.
4. The liquid crystal display device as claimed in claim 2, wherein both of the one of the pixels and the another of the pixels are disposed between the first one of the gate electrodes and the second one of the gate electrodes.
5. The liquid crystal display device as claimed in claim 4, wherein:
one of the openings is formed on the second one of the gate electrodes, the one of the openings being formed between the first one of the data electrodes and a second one of the data electrodes located by the one side of the first one of the data electrodes; and
another of the openings is formed on the first one of the gate electrodes, the another of the openings being formed between the first one of the data electrodes and a third one of the data electrodes located by the opposite side of the first one of the data electrodes.
6. The liquid crystal display device as claimed in claim 5, wherein:
no opening is formed on a portion of the first one of the gate electrodes located between the first one of the data electrodes and the second one of the data electrodes; and
no opening is formed on a portion of the second one of the gate electrodes located between the first one of the data electrodes and the third one of the data electrodes.
7. The liquid crystal display device as claimed in claim 1, wherein one of the pixels disposed by one side of one of the data electrodes and another of the pixels disposed by an opposite side of the one of the data electrodes are both coupled to the one of the data electrodes.
8. The liquid crystal display device as claimed in claim 7, wherein the one of the pixels and the another of the pixels are coupled to different ones of the gate electrodes.
9. The liquid crystal display device as claimed in claim 8, wherein the one of the pixels and the another of the pixels are both disposed between the different ones of the gate electrodes.
10. The liquid crystal display device as claimed in claim 1, wherein each of the openings exposes a portion of one of the gate electrodes located between two of the data electrodes.
11. The liquid crystal display device as claimed in claim 1, wherein each of the color filters is arranged between two of the openings.
12. The liquid crystal display device as claimed in claim 11, wherein the two of the openings are aligned in a direction substantially parallel to one of the data electrodes.
13. The liquid crystal display device as claimed in claim 1, wherein at least two of the color filters are arranged between nearest two of the openings.
14. The liquid crystal display device as claimed in claim 13, wherein the nearest two of the openings are aligned in a direction substantially parallel to one of the data electrodes.
15. The liquid crystal display device as claimed in claim 1, wherein at least two of the pixels are disposed between two of the data electrodes.
16. The liquid crystal display device as claimed in claim 15, wherein one of the at least two of the pixels is coupled to a first one of the gate electrodes, and another of the at least two of the pixels is coupled to a second one of the gate electrodes.
17. The liquid crystal display device as claimed in claim 15, wherein the one of the at least two of the pixels and the another of the at least two of the pixels are both formed between the first one of the gate electrodes and the second one of the gate electrodes.
18. The liquid crystal display device as claimed in claim 15, wherein:
one of the openings is formed on the second one of the gate electrodes at a location closer to the one of the at least two of the pixels than the another of the at least two of the pixels; and
another of the openings is formed on the first one of the gate electrodes at a location closer to the another of the at least two of the pixels than the one of the at least two of the pixels.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A conjugated compound comprising:
a) a ST receptor binding moiety; and
b) an active moiety;
wherein said active moiety is a radiostable active agent.
2. The compound of claim 1 wherein said ST receptor binding moiety is a peptide.
3. The compound of claim 1 wherein said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof.
4. The compound of claim 1 wherein said ST receptor binding moiety is selected from the group consisting of SEQ ID:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.
5. The compound of claim 1 wherein said active moiety is a therapeutic agent.
6. The compound of claim 1 wherein said active moiety is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipases C, bovine pancreatic ribonuclease, pokeweek antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.
7. The compound of claim 1 wherein:
a) said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof;
b) said an active moiety is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipases C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.
8. The compound of claim 1 wherein said an active moiety is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, cis-platin, vindesine, mitomycin and bleomycin, alkaline phosphatase, ricin A chain, Pseudomonas exotoxin and diphtheria toxin.
9. The compound of claim 1 wherein:
a) said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54; and
b) said an active moiety is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, cis-platin, vindesine, mitomycin and bleomycin, alkaline phosphatase, ricin A chain, Pseudomonas exotoxin and diphtheria toxin.
10. A pharmaceutical composition comprising:
a) a pharmaceutically acceptable carrier or diluent, and
b) a conjugate compound according to claim 1.
11. A method of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual a pharmaceutical composition according to claim 10.
12. A pharmaceutical composition comprising:
a) a pharmaceutically acceptable carrier or diluent, and,
b) conjugated compound comprising:
i) a ST receptor binding moiety; and
ii) an active moiety wherein said active moiety is a radioactive agent and said conjugated compound is present in an amount effective for therapeutic or diagnostic use in humans suffering from colorectal cancer.
13. The pharmaceutical composition of claim 12 wherein said active moiety is selected from the group consisting of: 47Sc, 67Cu, 90Y, 109Pd, 123I, 125I, 131I, 186Re, 199Au, 211At, 212Pb, 212B, 32P, 33P, 77Ge, 77As, 103Pb, 105Rh, 111Ag, 119Sb, 121Sn, 131Cs, 143Pr, 161Tb, 177Lu, 191Os, 193MPt and 197Hg.
14. The pharmaceutical composition of claim 12 wherein said active moiety is selected from the group consisting of: 43K, 52Fe, 57Co, 67Cu, 67Ga, 68Ga, 77Br, 81Rb81MKr, 87MSr, 99MTc, 111In, 113In, 123I, 125I, 127Cs, 129Cs, 131I, 132I, 197Hg, 203Pb and 206Bi.
15. The pharmaceutical composition of claim 12 wherein said ST receptor binding moiety is a peptide.
16. The pharmaceutical composition of claim 12 wherein said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof.
17. The pharmaceutical composition of claim 12 wherein said ST receptor binding moiety is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.
18. The pharmaceutical composition of claim 12 wherein said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54, and said active moiety is selected from the group consisting of: 47Sc, 67Cu, 90Y, 109Pd, 123I, 125I, 131I, 186Re, 188Re, 199Au, 211At, 212Pb, 212B, 32P and 33P, 71Ge, 77As, 103Pb, 105Rh, 111Ag, 119Sb, 121Sn, 131Cs, 143Pr, 161Tb, 177Lu, 191Os, 193MPt and 197Hg.
19. The pharmaceutical composition of claim 12 wherein said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO.5, SEQ ID NO:6 and SEQ ID NO:54, and said active moiety is selected from the group consisting of 43K, 53Fe, 57Co, 67Cu, 67Ga, 68Ga, 77Br, 81Rb81MKr, 87MSr, 99MTc, 111In, 123I, 125I, 127Cs, 129Cs, 131I, 132I, 197Hg, 203Pb and 206Bi.
20. A method of radioimaging metastasized colorectal cancer cells comprising the steps of administering to an individual a pharmaceutical composition comprising:
a) a pharmaceutically acceptable carrier or diluent, and
b) conjugated compound comprising:
i) a ST receptor binding moiety; and
ii) an active moiety;
wherein said active moiety is a radioactive agent and said conjugated compound is present in an amount effective for diagnostic use in humans suffering from colorectal cancer.
21. A method of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual a pharmaceutical composition comprising:
a) a pharmaceutically acceptable carrier or diluent, and,
b) conjugated compound comprising:
i) a ST receptor binding moiety; and
ii) an active moiety;
wherein said active moiety is a radiostable agent or radioactive agent and said conjugated compound is present in an amount effective for therapeutic or diagnostic use in humans suffering from colorectal cancer.
22. A method of delivery of a nucleic acid molecule to intestinal tract cells of an individual comprising the steps of administering to said individual a pharmaceutical composition comprising:
a) a pharmaceutically acceptable carrier or diluent, and,
b) a composition comprising:
i) a ST receptor ligand; and
ii) a nucleic acid molecule.
23. A method of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual:
a) a conjugated compound comprising an ST receptor binding moiety and an enzyme; and
b) a prodrug which when processed by the enzyme is converted to a drug.
24. The method of claims 23 wherein:
a) a conjugated compound comprises an ST receptor binding moiety and alkaline phosphatase; and
b) the prodrug is etoposidephosphate.
25. The compound of claim 1 wherein said active moiety is an enzyme.
26. The compound of claim 25 wherein said active moiety is alkaline phosphatase.